Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Oku

Showing results (21-30 of 86) with videos related to

Pageof 9
Sort By:
Journal of Clinical Laboratory Analysis|March 21, 2022
Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in JapanRisa Kaneshige, Yukari Motoki, Mika Yoshida, et al.
Internal Medicine (Tokyo, Japan)|February 17, 2017
Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and CyclophosphamideEri Sugawara, Masaru Kato, Ryo Hisada, et al.
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|March 7, 2015
[Clinical significance of antiphospholipid antibody measured by EliA anticardiolipin antibodies and anti-β2Glycoprotein I antibodies in antiphospholipid syndrome]Yuichiro Fujieda, Haruki Shida, Kenji Oku, et al.
Modern Rheumatology|June 20, 2023
Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: Analysis of the JCR COVID-19 registry in JapanYusuke Kashiwado, Yasutaka Kimoto, Kenji Oku, et al.
International Journal of Rheumatic Diseases|May 17, 2021
Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statementsKenji Oku, Laniyati Hamijoyo, Nuntana Kasitanon, et al.
Arthritis Care & Research|July 8, 2017
First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β<sub>2</sub> -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies TestsHiroyuki Nakamura, Kenji Oku, Olga Amengual, et al.
Modern Rheumatology|February 22, 2019
Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot studyAtsushi Noguchi, Shinsuke Yasuda, Ryo Hisada, et al.
Arthritis and Rheumatism|September 29, 2011
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic eventsKotaro Otomo, Tatsuya Atsumi, Olga Amengual, et al.
Plos One|July 24, 2025
A preliminary report on the feasibility of regression-based alignment of diagnostic thresholds for harmonized use of international classification criteria for antiphospholipid syndromeYukari Motoki, Risa Kaneshige, Yuichiro Fujieda, et al.
Rheumatology (Oxford, England)|December 4, 2018
Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndromeNaoki Ohnishi, Yuichiro Fujieda, Ryo Hisada, et al.
Pageof 9

Showing results (21-30 of 86) with videos related to

Sort By:
Pageof 9
Journal of Clinical Laboratory Analysis|March 21, 2022
Determination of diagnostic threshold in harmonization and comparison of clinical utility for five major antiphospholipid antibody assays used in JapanRisa Kaneshige, Yukari Motoki, Mika Yoshida, et al.
Internal Medicine (Tokyo, Japan)|February 17, 2017
Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and CyclophosphamideEri Sugawara, Masaru Kato, Ryo Hisada, et al.
Nihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|March 7, 2015
[Clinical significance of antiphospholipid antibody measured by EliA anticardiolipin antibodies and anti-β2Glycoprotein I antibodies in antiphospholipid syndrome]Yuichiro Fujieda, Haruki Shida, Kenji Oku, et al.
Modern Rheumatology|June 20, 2023
Prognostic improvement and treatment of COVID-19 in patients with rheumatic diseases until December 2022: Analysis of the JCR COVID-19 registry in JapanYusuke Kashiwado, Yasutaka Kimoto, Kenji Oku, et al.
International Journal of Rheumatic Diseases|May 17, 2021
Prevention of infective complications in systemic lupus erythematosus: A systematic literature review for the APLAR consensus statementsKenji Oku, Laniyati Hamijoyo, Nuntana Kasitanon, et al.
Arthritis Care & Research|July 8, 2017
First-Line, Non-Criterial Antiphospholipid Antibody Testing for the Diagnosis of Antiphospholipid Syndrome in Clinical Practice: A Combination of Anti-β<sub>2</sub> -Glycoprotein I Domain I and Anti-Phosphatidylserine/Prothrombin Complex Antibodies TestsHiroyuki Nakamura, Kenji Oku, Olga Amengual, et al.
Modern Rheumatology|February 22, 2019
Anti-cyclic citrullinated peptide antibody titers decrease in rheumatoid arthritis patients treated with tocilizumab: A pilot studyAtsushi Noguchi, Shinsuke Yasuda, Ryo Hisada, et al.
Arthritis and Rheumatism|September 29, 2011
Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic eventsKotaro Otomo, Tatsuya Atsumi, Olga Amengual, et al.
Plos One|July 24, 2025
A preliminary report on the feasibility of regression-based alignment of diagnostic thresholds for harmonized use of international classification criteria for antiphospholipid syndromeYukari Motoki, Risa Kaneshige, Yuichiro Fujieda, et al.
Rheumatology (Oxford, England)|December 4, 2018
Efficacy of dual antiplatelet therapy for preventing recurrence of arterial thrombosis in patients with antiphospholipid syndromeNaoki Ohnishi, Yuichiro Fujieda, Ryo Hisada, et al.
Pageof 9